NSE: DIVISLAB | BSE: 532488

Expensive Performer

Download real time

6124.50 20.50 (0.34%)

Near 52W High of ₹6308.50

402.6K NSE+BSE Volume

NSE 05 May, 2025 3:31 PM (IST)

162,586.2

Market Cap

Market Runner Up

0.7

Beta 1Year

Very Low volatility

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Search Inside the pdf :

Divi's Laboratories Ltd.

25 Mar 2025

6124.50

0.34%

DIVI' S LAB

Hold: Divi's Laboratories Ltd.

Target

Geojit BNP Paribas

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.

Divi's Laboratories Ltd.

05 Feb 2025, 12:00AM

6124.50

0.34%

High value projects will sustain growth in Custom Synthesis segment

Accumulate: Divi's Laboratories Ltd.

Target

KRChoksey

DIVISLAB revenue beat our estimates (+3.9%) due to strong growth in Custom Synthesis segment. EBITDA beat our estimates due to better-than-expected gross profit and lower than expected employee expenses. Adj. PAT was beat due to lower-than-expected effective tax rate.

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.

Divi's Laboratories Ltd.

04 Feb 2025

6124.50

0.34%

DIVI'S LABORATORIES

Accumulate: Divi's Laboratories Ltd.

Recommendation Target

Prabhudas Lilladhar

Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.

Divi's Laboratories Ltd.

03 Feb 2025

6124.50

0.34%

Custom synthesis drives earnings; generics stable QoQ

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

Divi’s Laboratories (DIVI) delivered in-line revenue. However, it reported better-than-expected EBITDA/PAT led by a better product mix and lower tax rate (due to the shift to a new tax regime).

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

03 Feb 2025

6124.50

0.34%

Divis Labs (HOLD): Back to higher growth trajectory

Hold: Divi's Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q3 sales/EBITDA/PAT were 0.6%/7.5%/22.3% above our estimates. PAT was higher than estimated due to the adoption of the new tax regime

Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.

Divi's Laboratories Ltd.

11 Nov 2024

6124.50

0.34%

Multiple growth levers to drive Custom Synthesis segment

Accumulate: Divi's Laboratories Ltd.

Target

KRChoksey

Divis Lab revenue beat our estimates significantly due to strong growth in the Custom Synthesis segment. EBITDA beat our estimate due to lower-than-expected other expenses and employee expenses.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

11 Nov 2024

6124.50

0.34%

Company set for continued growth

Buy: Divi's Laboratories Ltd.

Recommendation Target

Sharekhan

Divis Labs’ revenue for the quarter amounted to Rs. 2,238 crore, marking a 17% y-o-y increase and a 6% q-o-q rise, which was 4% above estimates.

Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.

Divi's Laboratories Ltd.

10 Nov 2024

6124.50

0.34%

Divi's Labs (SELL): Healthy Q2; rich valuations

Sell: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

DIVI reported healthy 2QFY25 earnings which was a beat on our estimates. Exports contributed 87% of sales and the US 71%

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

07 Aug 2024

6124.50

0.34%

Ramp up in custom synthesis and new generic APIs to drive margins

Hold: Divi's Laboratories Ltd.

Target

KRChoksey

DIVISLAB continues to post results below estimates due to continued weakness in generic pricing. We hence cut down our EPS estimates by 3% each for FY25E/FY26E.